Register for our free email digests:
Alex Shimmings
Latest From Alex Shimmings
AZ’s Fasenra Joins GSK’s Nucala In Nasal Polyp Pursuit Of Sanofi’s Dupixent
Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.
DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front
A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.
Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
Onconova On The Edge After Phase III Rigosertib MDS Failure
Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.
Novartis Hits Spartalizumab Phase III Setback In Melanoma
Novartis’s attempts to enter the PD1 market by combining its investigational immunotherapy spartalizumab with its Tafinlar and Mekinist BRAF/MEK combination have come unstuck, leaving Roche to the field.
Anti-Aging Firm Unity Stumbles At First Major Hurdle
Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.